Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: Is an additional vaccine needed or possible?

Vaccine

Volumn 24, Issue SUPPL. 2, 2006, Pages S65-

  Shinefield, Henry R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conjugated vaccines; Polysaccharide; S. aureus

Indexed keywords

EXOTOXIN; PLACEBO; POLYSACCHARIDE VACCINE; STAPHVAX; TOXOID; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY RESPONSE; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CLINICAL TRIAL; HOST RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; VACCINE PRODUCTION;

EID: 33645240457     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.126     Document Type: Article

References (29)

1. A. Gregerson, and R.S. Daum Staphylococcus aureus vaccine S. Plotkin W. Orenstein Vaccines 4th ed. 2004 Saunders Philadelphia p. 1347-55
2. S.K. Fridkin, J. Hageman, L.K. McDougal, J. Mohammed, W.R. Jarvis, and T.M. Perl Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 Clin Infect Dis 36 4 2003 429 439
3. P.C. Fuchs, A.L. Barry, and S.D. Brown In vitro bactericidal activity of daptomycin against staphylococci J Antimicrob Chemother 49 3 2002 467 470
4. B.E. Menzies, and D.S. Kernodle Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model Infect Immun 64 5 1996 1839 1841
5. R. Aly, H.R. Shinefield, C. Litz, and H.I. Maibach Role of teichoic acid in the binding of Staphylococcus aureus to nasal epithelial cells J Infect Dis 141 4 1980 463 465
6. C. Weidenmaier, J.F. Kokai-Kun, S.A. Kristian, T. Chanturiya, H. Kalbacher, and M. Gross Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections Nature Med 10 3 2004 243 245
7. P. Moreillon, J.M. Entenza, P. Francioli, D. McDevitt, T.J. Foster, and P. Francois Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis Infect Immun 63 12 1995 4738 4743
8. B.E. Menzies The role of fibronectin binding proteins in the pathogenesis of Staphylococcus aureus infections Curr Opin Infect Dis 16 3 2003 225 229
9. Stinson JR, Lopez V, Grinberg L, Mond JJ. The murine antibody response to lipoteichoic acid: linkage between innate and adaptive immunity. Presented at: Experimental Biology April 17-21, 2004; Washington, DC.
10. Weisman LE, Thackray HM, Gracia-Prats JA, Nesin M, Mond J, Schneider JH, et al. Phase I/II double blind, placebo controlled, dose escalation, safety and pharmacokinetics study in very low birth weight neonates of BSYX-A110, an anti-staphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections [abstract LB14]. Presented at: Pediatric Academic Societies Annual Meeting May 1-4, 2004; San Francisco, CA.
11. H.R. Shinefield, J.C. Ribble, M. Boris, H.F. Eichenwald, R. Aly, and H. Maibach Bacterial interference between strains of S. aureus Ann NY Acad Sci 236 0 1974 444 455
12. R.W. Steele Recurrent staphylococcal infection in families Arch Dermatol 116 2 1980 189 190
13. R.P. Novick, H.F. Ross, S.J. Projan, J. Kornblum, B. Kreiswirth, and S. Moghazeh Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule EMBO J 12 10 1993 3967 3975
14. G. Ji, R. Beavis, and R.P. Novick Bacterial interference caused by autoinducing peptide variants Science 276 5321 1997 2027 2030
15. P. Mayville, G. Ji, R. Beavis, H. Yang, M. Goger, and R.P. Novick Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence Proc Natl Acad Sci USA 96 4 1999 1218 1223
16. G.J. Lyon, P. Mayville, T.W. Muir, and R.P. Novick Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC Proc Natl Acad Sci USA 97 24 2000 13330 13335
17. R. Ghiselli, A. Giacometti, O. Cirioni, G. Dell'Acqua, F. Mocchegiani, and F. Orlando RNAIII-inhibiting peptide and/or Nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant staphylococcus epidermidis Eur J Vasc Endovasc Surg 27 6 2004 603 607
18. O. Cirioni, A. Giacometti, R. Ghiselli, G. Dell'Acqua, Y. Gov, and W. Kamysz Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides Circulation 108 6 2003 767 771
19. E.B. Hume, J.J. Dajcs, J.M. Moreau, and R.J. O'Callaghan Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis Infect Immun 68 10 2000 6052 6055
20. C. Adlam, P.D. Ward, A.C. McCartney, J.P. Arbuthnott, and C.M. Thorley Effect immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits Infect Immun 17 2 1977 256 259
21. L.A. Poole-Warren, M.D. Hallett, P.W. Hone, S.H. Burden, and P.C. Farrell Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial Clin Nephrol 35 5 1991 198 206
22. J. Gampfer, V. Thon, H. Gulle, H.M. Wolf, and M.M. Eibl Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome Vaccine 20 9-10 2002 1354 1364
23. D.L. Hu, K. Omoe, S. Sasaki, H. Sashinami, H. Sakuraba, and Y. Yokomizo Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection J Infect Dis 188 5 2003 743 752
24. A.I. Fattom, J. Sarwar, A. Ortiz, and R. Naso A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP- specific antibodies protect mice against bacterial challenge Infect Immun 64 5 1996 1659 1665
25. A. Fattom, R. Schneerson, D.C. Watson, W.W. Karakawa, D. Fitzgerald, and I. Pastan Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A Infect Immun 61 3 1993 1023 1032
26. P.G. Welch, A. Fattom, J. Moore Jr., R. Schneerson, J. Shiloach, and D.A. Bryla Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis J Am Soc Nephrol 7 2 1996 247 253
27. H. Shinefield, S. Black, A. Fattom, G. Horwith, S. Rasgon, and J. Ordonez Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis N Engl J Med 346 7 2002 491 496
28. H. Etz, D.B. Minh, T. Henics, A. Dryla, B. Winkler, and C. Triska Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus Proc Natl Acad Sci USA 99 10 2002 6573 6578
29. T. Weichhart, M. Horky, J. Sollner, S. Gangl, T. Henics, and E. Nagy Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro Infect Immun 71 8 2003 4633 4641